B. In the Claims

Please amend claims 14 and 21 and cancel claims 1 to 13 without prejudice.

Upon entry of the present amendment, the status of the claims will be as follows:

Claims 1 to 13 (cancelled).

14. (currently amended) A method of detecting a cell proliferative disorder comprising contacting ~~the antibody of claim 11~~ an antibody reactive with substantially pure growth differentiation factor-6 (GDF-6) and functional fragments thereof with a specimen of a subject suspected of having a GDF-6 associated disorder and detecting binding of the antibody.

15. (original) The method of claim 14, wherein the cell is a placental cell.

16. (original) The method of claim 14, wherein the detecting is *in vivo*.

17. (original) The method of claim 16, wherein the antibody is detectably labeled.

18. (original) The method of claim 17, wherein the detectable label is selected from the group consisting of a radioisotope, a fluorescent compound, a bioluminescent compound and a chemiluminescent compound.

19. (original) The method of claim 14, wherein the detection is *in vitro*.

20. (original) The method of claim 19, wherein the antibody is detectably labeled.

21. (currently amended) The method of claim 20, wherein the label is selected from the group consisting of a radioisotope, a fluorescent compound, a bioluminescent compound, a ~~chemoluminensceent~~ chemiluminescent compound and an enzyme.

22. (original) A method of treating a cell proliferative disorder associated with expression of GDF-6, comprising contacting the cells with a reagent which suppresses the GDF-6 activity.

23. (original) The method of claim 22, wherein the reagent is an anti-GDF-6 antibody.

24. (original) The method of claim 22, wherein the reagent is a GDF-6 antisense sequence.

25. (original) The method of claim 22, wherein the cell is a placental cell.

26. (original) The method of claim 22, wherein the reagent which suppresses GDF-6 activity is introduced to a cell using a vector.

27. (original) The method of claim 26, wherein the vector is a colloidal dispersion system.

28. (original) The method of claim 27, wherein the colloidal dispersion system is a liposome.

29. (original) The method of claim 28, wherein the liposome is essentially target specific.

30. (original) The method of claim 29, wherein the liposome is anatomically targeted.

31. (original) The method of claim 30, wherein the liposome is mechanistically targeted.

32. (original) The method of claim 31, wherein the mechanistic targeting is passive.

33. (original) The method of claim 31, wherein the mechanistic targeting is active.

34. (original) The method of claim 33, wherein the liposome is actively targeted by coupling with a moiety selected from the group consisting of a sugar, a glycolipid, and a protein.

35. (original) The method of claim 34, wherein the protein moiety is an antibody.

36. (original) The method of claim 35, wherein the vector is a virus.

37. (original) The method of claim 36, wherein the virus is an RNA virus.

38. (original) The method of claim 37, wherein the RNA virus is a retrovirus.

39. (original) The method of claim 38, wherein the retrovirus is essentially target specific.

40. (original) The method of claim 39, wherein the moiety for target specificity is encoded by a polynucleotide inserted into the retroviral genome.

41. (original) The method of claim 40, wherein the moiety for target specificity is selected from the group consisting of a sugar, a glycolipid, and a protein.

42. (original) The method of claim 41, wherein the protein is an antibody.